-
Palomid 529: Applied PI3K/Akt/mTOR Inhibition in Cancer Rese
2026-06-09
Palomid 529 (P529) delivers dual mTORC1/mTORC2 inhibition for robust suppression of oncogenic signaling in advanced cancer models. This guide details optimized workflows, troubleshooting strategies, and key insights for leveraging P529 in translational research targeting tumor progression and resistance.
-
SLC7A14 in Hypothalamic POMC Neurons Regulates Age-Related L
2026-06-09
This study uncovers a novel mechanism by which reduced SLC7A14 expression in hypothalamic POMC neurons impairs white adipose tissue (WAT) lipolysis during aging in male mice. The findings illuminate a central regulatory pathway involving the SLC7A14–TCDCA–mTORC1 axis and its connection to brain–gut–adipose tissue signaling, with implications for metabolic aging research.
-
Redefining Apoptosis Detection: Strategic Advances for Trans
2026-06-08
This thought-leadership article explores how the Annexin V-Cy5/DAPI Apoptosis Kit empowers translational researchers to dissect cell death mechanisms with unprecedented specificity. Integrating mechanistic insights from recent leukemia research, we examine the evolving landscape of apoptosis assays, highlight protocol best practices, and position APExBIO’s kit as a pivotal tool for driving next-generation discoveries in cell death biology.
-
Pemetrexed in Cancer Chemotherapy Research: Protocols & Insi
2026-06-08
Pemetrexed disodium is a cornerstone for advanced cancer chemotherapy research, uniquely enabling the interrogation of nucleotide biosynthesis and DNA repair vulnerabilities in tumor models. This guide delivers actionable workflows, troubleshooting strategies, and translational context for maximizing results when deploying APExBIO’s rigorously validated Pemetrexed.
-
Indole-3-pyruvic Acid (SKU C8759): Bench-Validated Solutions
2026-06-07
This article delivers scenario-driven, evidence-based guidance for leveraging Indole-3-pyruvic acid (SKU C8759) in immunology and cell-based assays. With practical Q&A blocks, quantitative literature references, and real-world workflow recommendations, it empowers researchers to advance reproducibility and sensitivity using validated IPA protocols.
-
Reelin–Src Signaling: A Permissive Gate for Ketamine Antidep
2026-06-06
This study reveals that intact Reelin–Apoer2–Src kinase signaling is essential for ketamine to induce synaptic and behavioral antidepressant effects. Disruption of this pathway blocks ketamine-mediated synaptic potentiation, providing mechanistic insight into patient nonresponsiveness and highlighting new research directions.
-
MiR-3180 Suppresses HCC Growth by Targeting Lipid Metabolism
2026-06-05
Hong et al. reveal that miR-3180 inhibits hepatocellular carcinoma (HCC) growth and metastasis by downregulating SCD1 and CD36, critical regulators of lipid synthesis and uptake. These findings position miR-3180 as a promising therapeutic and prognostic target in HCC.
-
Romidepsin (FK228): Selective HDAC Inhibition for Cancer Epi
2026-06-05
Romidepsin (FK228) is a potent, selective class I HDAC inhibitor widely used in cancer epigenetics research. It demonstrates nanomolar potency against HDAC1/2, induces apoptosis and cell cycle arrest, and is a benchmark tool for chromatin remodeling studies.
-
Indole-3-pyruvic Acid: Mechanisms, Evidence, and Workflow Ut
2026-06-04
Indole-3-pyruvic acid (IPA) is a key tryptophan metabolite involved in auxin biosynthesis, immune modulation, and cancer pathways. Mechanistic evidence supports its role as a UHRF1 inhibitor and AMPK activator. IPA's relevance extends across plant biology, immunology, and oncology.
-
Bradykinin (SKU BA5201): Protocols for Endothelium-Dependent
2026-06-04
Bradykinin (SKU BA5201) is a research-grade endothelium-dependent vasodilator peptide optimized for cardiovascular, pain mechanism, and inflammation pathway studies. It addresses experimental needs for acute vascular permeability modulation, smooth muscle contraction research, and related in vitro assays. Not intended for diagnostic or clinical use; product application is limited to controlled laboratory research.
-
SGI-1027 and Everolimus Synergy in Renal Cancer via Lysosoma
2026-06-03
This study demonstrates that SGI-1027, a DNMT1 inhibitor, synergizes with everolimus to induce apoptosis and pyroptosis in renal cell carcinoma by promoting lysosomal membrane permeability. The findings advance the understanding of overcoming everolimus resistance and establish a mechanistic foundation for combination therapies in advanced RCC.
-
ROS-Degradable Lipid Nanoparticles Enable Tumor-Selective mR
2026-06-03
The referenced study introduces a combinatorial library of ROS-degradable lipid nanoparticles that selectively deliver mRNA into tumor cells by leveraging elevated intracellular ROS. This innovation enhances the specificity and efficacy of mRNA-based therapeutics, highlighting a promising strategy for targeted cancer gene therapy.
-
CPSIT_0844 Drives IL-6/IL-8 Induction via TLR2/4 and JNK Pat
2026-06-02
This study identifies the Chlamydia psittaci inclusion membrane protein CPSIT_0844 as a potent inducer of IL-6 and IL-8 in human monocytes through TLR2/TLR4-MyD88 signaling, implicating MAPK and NF-κB pathways. These findings clarify a molecular mechanism behind C. psittaci-driven inflammation, informing future research on cytokine regulation and host-pathogen interactions.
-
FGFR and PI3K/AKT Cross Talk Regulates Periostin in HER2+ Br
2026-06-02
Labrèche et al. (2021) reveal that periostin gene expression in HER2-positive breast cancer cells is tightly regulated by signaling cross talk between FGFR, TGFβ, and PI3K/AKT pathways. This study elucidates a previously uncharacterized mechanism of tumor cell adaptation with implications for understanding aggressive cancer phenotypes and potential pathway-targeted interventions.
-
AMH-SMAD4 Pathway Modulates Granulosa Cell Fate in PCOS Rats
2026-06-01
This study elucidates how anti-Müllerian hormone (AMH) regulates ovarian granulosa cell proliferation and apoptosis in a rat model of polycystic ovary syndrome (PCOS) via the SMAD4 pathway. These mechanistic findings clarify the cellular dysfunction underlying abnormal follicle formation in PCOS and suggest new molecular targets for reproductive research.